Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

Characterisation of human pancreatic mesenchymal stromal cells in type 1 diabetes

Dewhurst-Trigg RE., Atkins J., Morgan NG., Eichmann M., Richardson SJ., Rackham CL.

Laboratory Study on Type 1 Diabetes, published in Diabetologia (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Diabetologia (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41422462
PMCID
PMC12957432
DOI
10.1007/s00125-025-06634-w

Abstract (original English)

Aims/hypothesis Culture-expanded mesenchymal stromal cells (MSCs) reduce immune cell activation and improve islet functional survival. However, little is known about human pancreatic MSCs (pMSCs) in health or how they are altered in type 1 diabetes. Here, we determined the number, density and islet-protective phenotype of pMSCs in situ in individuals with and without type 1 diabetes. Methods Multiplex immunohistochemistry was used to identify pMSCs (CD90 + /CD105 + /CD73 + /CD31 - /CD45 - /CD34 - ) in human pancreas sections from 38 donors (Network for Pancreatic Organ Donors with Diabetes and Exeter Archival Diabetes Biobank). Donors were categorised as either Results pMSCs were identified in situ in the human pancreas where they wrap around the islet periphery in an expected spindle-like morphology. ANXA1 was expressed by 33.2% of pMSCs and was expressed constitutively among individuals with or without diabetes. The density of both intraislet pMSCs and pMSCs within 10 µm of the islet periphery was increased for insulin-containing islets in individuals with type 1 diabetes compared with individuals without diabetes (p Conclusions/interpretation pMSCs express ANXA1 constitutively, suggesting an islet-protective role in health. The density of pMSCs was increased around insulin-containing islets and lost around insulin-deficient islets in individuals with type 1 diabetes which al

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
PancreasIslets of LangerhansMesenchymal Stem CellsHumansDiabetes Mellitus, Type 1InsulinImmunohistochemistryAdolescentAdultMiddle Aged

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research